Trulicity (dulaglutide) is a prescription injectable medication approved for the treatment of type 2 diabetes. It is part of the GLP-1 receptor agonist drug class, which works by lowering blood sugar, suppressing appetite, and slowing digestion.
Although Trulicity is generally prescribed at lower doses than newer GLP-1 drugs, serious side effects have still been reported, including severe gastrointestinal injury, kidney complications, gallbladder disease, pancreatitis, and vision problems such as NAION. As GLP-1 safety investigations expand, Trulicity is included in broader litigation and injury reviews involving this drug class.
Trulicity is a weekly (1 x a week), injectable drug utilized to enhance blood sugar control (HbA1c) in people 18 and over and children over 10 years old who suffer with type 2 diabetes. It is recommended that patients also engage in diet and exercise. Trulicity is a GLP-1 receptor agonist. It assists the pancreas to release insulin, lowers liver glucose production, and inhibits (slows) digestion. It is also approved to reduce the risk of major cardiovascular events like heart attacks or strokes in adults with heart disease.
Its recommended usage is to be injected below the skin (subcutaneous) in the abdomen, thigh, or upper arm. Typically, the most usual complications are nausea, vomiting, diarrhea, stomach pain, and less appetite. Trulicity has a scarlet letter of a boxed warning for possible thyroid C-cell tumors. Trulicity may result in pancreatitis, severe hypoglycemia (when utilized along with insulin) as well as damage to the kidney. Trulicity operates as a GLP-1 receptor agonist, mimicking a natural hormone that is released after eating. This helps regulate blood sugar by increasing insulin secretion, lowering glucagon, and reducing appetite.
This page provides a comprehensive overview of Trulicity, how it works, known risks, and when medical or legal review may be appropriate.
What Is Trulicity?
Trulicity is an injectable medication containing dulaglutide.
Key facts:
- FDA-approved for type 2 diabetes
- Injected once weekly
- Manufactured by Eli Lilly
- Not FDA-approved for weight loss
- Part of the GLP-1 receptor agonist drug class
Trulicity was one of the earlier GLP-1 drugs, prescribed before semaglutide and tirzepatide became widespread.
How Trulicity Works
Trulicity mimics the hormone GLP-1, which:
- increases insulin release
- decreases glucagon secretion
- slows stomach emptying
- suppresses appetite
- affects gut-brain signaling
Although effective for blood sugar control, these mechanisms can also disrupt normal digestion in some patients.
Approved Uses and Prescribing Context
FDA-Approved Use
- Blood sugar control in adults with type 2 diabetes
Off-Label Context
While not approved for weight loss, some patients experience:
- appetite suppression
- unintentional weight loss
Long-term use or dose escalation may increase side-effect risk.
Commonly Reported Side Effects
Many Trulicity users report gastrointestinal symptoms, especially early in treatment:
- nausea
- vomiting
- diarrhea
- constipation
- abdominal pain
- bloating
- fatigue
- dizziness
For some patients, these symptoms persist or worsen over time.
Serious Safety Concerns Associated With Trulicity
Severe Gastrointestinal Motility Disorders
Reported injuries include:
- gastroparesis (stomach paralysis)
- ileus (functional bowel shutdown)
- severe constipation
- chronic digestive dysfunction
➡️ Related: Motility Disorders
Dehydration & Kidney Injury
Ongoing vomiting or diarrhea may lead to:
- dehydration
- electrolyte imbalance
- acute kidney injury (AKI)
- worsening kidney disease
➡️ Related: Dehydration and Kidney Damage
Gallbladder Disease
Weight loss and altered bile flow may increase the risk of:
- gallstones
- gallbladder inflammation
- gallbladder removal surgery
➡️ Related: Gallbladder Removal
Pancreatitis
Some patients report:
- severe abdominal pain
- elevated pancreatic enzymes
- hospitalization for pancreatitis
➡️ Related: Pancreatitis
Vision Problems / NAION
Serious vision complications, including Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), have been reported across the GLP-1 drug class.
➡️ Related:
Who May Be at Higher Risk
Higher-risk patients may include:
- those with prior GI disorders
- individuals prone to dehydration
- patients with kidney disease
- people with diabetes-related vascular disease
- older adults
- long-term GLP-1 users
Trulicity and Lawsuits
Trulicity is included in broader GLP-1 litigation, particularly claims involving:
- severe motility disorders
- kidney injury
- gallbladder surgery
- pancreatitis
- permanent digestive injury
- blindness / NAION
➡️ Trulicity lawsuits hub: Lawsuits
When to Consider a Review
You may want to consider review if:
- you used Trulicity, AND
- you required ER care or hospitalization, OR
- you developed a diagnosed complication, OR
- symptoms persisted after stopping the drug
➡️ Start here: File a Claim
Trulicity is an established GLP-1 medication that helps control blood sugar but may cause serious and persistent side effects in some patients. While many tolerate the drug, others report long-term or life-altering injuries.
If you experienced severe complications after using Trulicity, medical and legal review may be appropriate.